Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-03T05:09:27.677Z Has data issue: false hasContentIssue false

61 - Squamous-cell carcinoma

from Part 3.3 - Molecular pathology: cancers of the skin

Published online by Cambridge University Press:  05 February 2015

Carter Van Waes
Affiliation:
Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA
Yansong Bian
Affiliation:
Laboratory of Cell and Developmental Biology, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA
Clint T. Allen
Affiliation:
Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA
John C. Morris
Affiliation:
Metabolism Branch, National Cancer Institute, NIH, Bethesda, MD, USA
Zhong Chen
Affiliation:
Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA
Edward P. Gelmann
Affiliation:
Columbia University, New York
Charles L. Sawyers
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Frank J. Rauscher, III
Affiliation:
The Wistar Institute Cancer Centre, Philadelphia
Get access

Summary

Introduction

Squamous-cell carcinomas (SCCs) form the predominant histological type of cancers arising from the head and neck (HNSCC; oral and nasal cavities, paranasal sinuses, pharynx, and larynx), uterine cervix, and skin; and a subset of carcinomas arising from the lung and esophagus (1). Those arising in the head and neck, lung, and esophagus are predominantly associated with tobacco and alcohol use, which contain polyaromatic hydrocarbons, sulphites, and acetaldehydes that can induce mutagenesis of key tumor-suppressor genes, such as CDKN2A and TP53, or mutagenesis or over-expression of oncogenes, such as EGFR, c-MET, or RAS. Most cervical SCC, and a subset of SCC arising in the oropharynx and skin of the anogential region, are associated with human papilloma viruses (HPVs). These viruses encode E6 and E7 oncogenes that inactivate important tumor-suppressor proteins TP53 and RB, and activate nuclear factor-kappaB (NF-κB). A subset of nasopharygeal carcinomas is associated with Epstein–Barr viruses (EBVs), which express LMP-1, an oncogene that also activates NF-κB. Most skin SCC arise in sun-exposed areas due to ultraviolet-light-induced carcinogenesis. Because much of what has been learned about the molecular pathogenesis of tobacco and HPV-related HNSCC applies to lung, esophageal, or cervical SCC, emphasis will be given to alterations common to HNSCC and SCC arising from these sites.

Tumor-suppressor genes in SCC

A genetic progression model for HNSCC has been defined by micro-satellite analysis for allelic loss at multiple loci (2). Important tumor-suppressor genes altered by genetic and epigenetic events and their consequences are illustrated in Figure 61.1, left side. A locus at 9p21 frequently undergoes loss of heterozygosity (LOH) during development of squamous hyperplasia and SCC (2). This locus encodes proteins p16INK4a and p14ARF, and is inactivated in the majority of HNSCC by homozygous deletion, mutation, or by methylation of the regulatory promoter region (3). The p16INK4a protein is a cyclin-dependent kinase (CDKN2A/MTS-1/INK4A) that inhibits cell-cycle progression. Re-expression of p16INK4a in HNSCC cells by gene transfer suppresses cell growth in vitro (4). p14ARF is an important activator of the TP53 tumor-suppressor pathway and repressor of the NF-κB pro-survival pathway (5,6). Re-expression of p14ARF has been shown to reactivate TP53, and repress NF-κB-mediated pro-survival gene expression and promote cell death in other cell lines (6). Thus, genetic or epigenetic alteration of this locus can result in loss of p16INK4a, causing increased proliferation, and p14ARF protein, causing decreased programmed cell death.

Type
Chapter
Information
Molecular Oncology
Causes of Cancer and Targets for Treatment
, pp. 686 - 692
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suo, Z, Holm, R, Nesland, JM. Squamous cell carcinomas. An immunohistochemical study of cytokeratins and involucrin in primary and metastatic tumours. Histopathology 1993;23:45–54.CrossRefGoogle ScholarPubMed
Califano, J, van der Riet, P, Westra, W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Research 1996;56:2488–92.Google ScholarPubMed
Reed, AL, Califano, J, Cairns, P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Research 1996;56:3630–3.Google ScholarPubMed
Liggett WH Jr, Sewell, DA, Rocco, J, et al. p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Research 1996;56:4119–23.Google Scholar
Lowe, SW, Sherr, CJ.Tumor suppression by Ink4a-Arf: progress and puzzles. Current Opinion in Genetic Development 2003;13:77–83.CrossRefGoogle ScholarPubMed
Rocha, S, Garrett, MD, Campbell, KJ, Schumm, K, Perkins, ND.Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO Journal 2005;24:1157–69.CrossRefGoogle ScholarPubMed
Gorgoulis, V, Rassidakis, G, Karameris, A, et al. Expression of p53 protein in laryngeal squamous cell carcinoma and dysplasia: possible correlation with human papillomavirus infection and clinicopathological findings. Virchows Archiv 1994;425:481–9.CrossRefGoogle ScholarPubMed
Gillison, ML, Koch, WM, Capone, RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Journal of the National Cancer Institute 2000;92:709–20.CrossRefGoogle Scholar
Crook, T, Wrede, D, Tidy, JA, et al. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet 1992;339:1070–3.CrossRefGoogle ScholarPubMed
Friedman, J, Nottingham, L, Duggal, P et al. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clinical Cancer Research 2007;13: 6568–78.CrossRefGoogle ScholarPubMed
Sidransky, D, Hollstein, M.Clinical implications of the p53 gene. Annual Review of Medicine 1996;47:285–301.CrossRefGoogle ScholarPubMed
Lerman, MI, Minna, JD.The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Research 2000;60:6116–33.Google ScholarPubMed
Kuroki, T, Trapasso, F, Yendamuri, S, et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Research 2003;63:3724–8.Google ScholarPubMed
Herzog, CR, Crist, KA, Sabourin, CL, et al. Chromosome 3p tumor suppressor gene alterations in cervical carcinomas. Molecular Carcinogenesis 2001;30:159–68.CrossRefGoogle ScholarPubMed
Lu, SL, Herrington, H, Reh, D, et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes and Development 2006;20:1331–42.CrossRefGoogle ScholarPubMed
Okami, K, Wu, L, Riggins, G, et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Research 1998;58:509–11.Google ScholarPubMed
Madrid, LV, Mayo, MW, Reuther, JY, Baldwin, AS. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. Journal of Biological Chemistry 2001;276:18 934–40.CrossRefGoogle ScholarPubMed
Amornphimoltham, P, Patel, V, Sodhi, A, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Research 2005;65:9953–61.CrossRefGoogle ScholarPubMed
Grandis, JR, Tweardy, DJ.Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Research 1993;53:3579–84.Google ScholarPubMed
Grandis, JR, Melhem, MF, Gooding, WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. Journal of the National Cancer Institute 1998;90:824–32.CrossRefGoogle Scholar
Sheu, JJ, Hua, CH, Wan, L, et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Research 2009;69:2568–76.CrossRefGoogle ScholarPubMed
Sok, JC, Coppelli, FM, Thomas, SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clinical Cancer Research 2006;12:5064–73.CrossRefGoogle ScholarPubMed
Hirsch, FR, Varella-Garcia, M, Bunn, PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. Journal of Clinical Oncology 2003;21:3798–807.CrossRefGoogle ScholarPubMed
Itakura, Y, Sasano, H, Shiga, C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma: an immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74:795–804.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
Seiwert, TY, Jagadeeswaran, R, Faoro, L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Research 2009;69:3021–31.CrossRefGoogle ScholarPubMed
Beau-Faller, M, Ruppert, AM, Voegeli, AC, et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. Journal of Thoracic Oncology 2008;3:331–9.CrossRefGoogle Scholar
Dong, G, Chen, Z, Li, ZY, et al. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines IL-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Research 2001;61:5911–18.Google ScholarPubMed
Okami, K, Reed, AL, Cairns, P, et al. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 1999;18:3541–5.CrossRefGoogle ScholarPubMed
Hibi, K, Trink, B, Patturajan, M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proceedings of the National Academy of Sciences USA 2000;97:5462–7.CrossRefGoogle ScholarPubMed
Stiewe, T.The p53 family in differentiation and tumorigenesis. Nature Reviews Cancer 2007;7:165–8.CrossRefGoogle ScholarPubMed
Rocco, JW, Leong CO, Kuperwasser, N, DeYoung, MP, Ellisen, LW.p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006;9:45–56.CrossRefGoogle ScholarPubMed
King, KE, Ponnamperuma, RM, Allen, C, et al. The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth. Cancer Research 2008;68:5122–31.CrossRefGoogle ScholarPubMed
Lu, H, Duggal, P, Allen C et al. TNF-alpha promotes c-REL/DeltaNp63alpha interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. Cancer Research 2011;71:6867–77.CrossRefGoogle ScholarPubMed
Alter, BP. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology American Society of Hematology Education Program 2007:29–39.
SA, Dokal, I, Armanios, M, et al. Dyskeratosis congenita: the first NIH clinical research workshop. Pediatric Blood Cancer 2009;53:520–3.Google Scholar
Prime, SS, Thakker, NS, Pring, M, Guest, PG, Paterson, IC.A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma. Oral Oncology 2001;37:1–16.CrossRefGoogle ScholarPubMed
van Zeeburg, HJ, Snijders, PJ, Wu, T, et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. Journal of the National Cancer Institute 2008;100:1649–53.CrossRefGoogle ScholarPubMed
Kutler, DI, Wreesmann, VB, Goberdhan, A, et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. Journal of the National Cancer Institute 2003;95:1718–21.CrossRefGoogle ScholarPubMed
Lee, TL, Yang, XP, Yan, B, et al. A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clinical Cancer Research 2007;13:5680–91.CrossRefGoogle ScholarPubMed
Cohen, J, Chen, Z, Lu, SL, et al. Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer. Cancer Research 2009;69:3415–24.CrossRefGoogle ScholarPubMed
Lee, TL, Yeh, J, Friedman, J, et al. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. International Journal of Cancer 2008;122:1987–98.CrossRefGoogle ScholarPubMed
Webster, GA, Perkins, ND.Transcriptional cross talk between NF-kappaB and p53. Molecular and Cellular Biology 1999;19:3485–95.CrossRefGoogle ScholarPubMed
James, MA, Lee, JH, Klingelhutz, AJ.Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. Journal of Virology 2006;80:5301–7.CrossRefGoogle Scholar
Hoover, AC, Strand, GL, Nowicki, PN, et al. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene 2009;28:3960–70.CrossRefGoogle ScholarPubMed
Cohen, J, Chen, Z, Lu, SL, et al. Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer. Cancer Research 2009;69:3415–24.CrossRefGoogle ScholarPubMed
Kresty, LA, Mallery, SR, Knobloch, TJ.Frequent alterations of p16INK4a and p14ARF in oral proliferative verrucous leukoplakia. Cancer Epidemiology, Biomarkers and Prevention 2008;17:3179–87.CrossRefGoogle ScholarPubMed
Hoffmann, TK, Sonkoly, E, Hauser, U, et al. Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncology 2008;44:1100–9.CrossRefGoogle ScholarPubMed
Kanellou, P, Zaravinos, A, Zioga, M, et al. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis. Cancer Letters 2008;264:145–61.CrossRefGoogle ScholarPubMed
Küsters-Vandevelde, HV, Van Leeuwen, A, Verdijk, MA, et al. CDKN2A but not TP53 mutations nor HPV presence predict poor outcome in metastatic squamous cell carcinoma of the skin. International Journal of Cancer 2010;126:2123–32.Google Scholar
Mallakin, A, Sugiyama, T, Taneja, P, et al. Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell 2007;12:381–94.CrossRefGoogle ScholarPubMed
Poeta, ML, Manola, J, Goldwasser, MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. New England Journal of Medicine 2007;357:2552–61.CrossRefGoogle ScholarPubMed
Strano, S, Dell’Orso, S, Di Agostino, S, et al. Mutant p53: an oncogenic transcription factor. Oncogene 2007;26:2212–19.CrossRefGoogle Scholar
Patel, S, Player, MR.Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opinion on Investigational Drugs 2008;17:1865–82.CrossRefGoogle ScholarPubMed
Strano, S, Dell’Orso, S, Di Agostino, S, et al. Mutant p53: an oncogenic transcription factor. Oncogene 2007;26:2212–19.CrossRefGoogle Scholar
Carroll, DK, Carroll, JS, Leong, CO, et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nature Cell Biology 2006;8:551–61.CrossRefGoogle ScholarPubMed
Ratovitski, EA, Patturajan, M, Hibi, K, et al. p53 associates with and targets Delta Np63 into a protein degradation pathway. Proceedings of the National Academy of Sciences USA 2001;98:1817–22.CrossRefGoogle ScholarPubMed
Lanza, M, Marinari, B, Papoutsaki, M, et al. Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutants. Cell Cycle 2006;5:1996–2004.CrossRefGoogle ScholarPubMed
Lee, JW, Soung, YH, Kim, SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clinical Cancer Research 2005;11: 2879–82.CrossRefGoogle ScholarPubMed
Egloff, AM, Grandis, JR.Improving response rates to EGFR-targeted therapies for head and neck squamous cell carcinoma: candidate predictive biomarkers and combination treatment with Src inhibitors. Journal of Oncology 2009:896407.Google Scholar
Lee, TL, Yeh, J, Van Waes, C, Chen, Z.Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Molecular Cancer Therapeutics 2006;5:8–19.CrossRefGoogle ScholarPubMed
Grandis, JR, Drenning, SD, Zeng, Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proceedings of the National Academy of Sciences USA 2000;97:4227–32.CrossRefGoogle ScholarPubMed
Pernas, FG, Allen, CT, Winters, ME, et al. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clinical Cancer Research 2009;15:2361–72.CrossRefGoogle ScholarPubMed
Birchmeier, C, Birchmeier, W, Gherardi, E, Vande Woude, GF.Met, metastasis, motility and more. Nature Reviews Molecular and Cellular Biology 2003;4:915–2564.CrossRefGoogle ScholarPubMed
Allen, C, Duffy, S, Teknos, T, et al. NF-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clinical Cancer Research 2007;13:3182–90.CrossRefGoogle Scholar
Clayman, GL.The current status of gene therapy. Seminars in Oncology 2000;27:39–43Google ScholarPubMed
Muller, P, Hrstka, R, Coomber, D, Lane, DP, Vojtesek, B.Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008;27:3371–83.CrossRefGoogle ScholarPubMed
Bonner, JA, Harari, PM, Giralt, J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine 2006;354:567–78CrossRefGoogle ScholarPubMed
Burtness, B, Goldwasser, MA, Flood, W, Mattar, B, Forastiere, AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 2005; 23:8646–54CrossRefGoogle ScholarPubMed
Cohen, EE, Halpern, AB, Kasza, K, et al. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncology 2009;45:e155–60.CrossRefGoogle ScholarPubMed
Eder, JP, Vande Woude, GF, Boerner, SA, LoRusso, PM.Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clinical Cancer Research 2009;15:2207–14.CrossRefGoogle Scholar
Comoglio, PM, Giordano, S, Trusolino, L.Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Reviews Drug Discovery 2008;7:504–16.CrossRefGoogle ScholarPubMed
Leeman, RJ, Lui, VW, Grandis, JR.STAT3 as a therapeutic target in head and neck cancer. Expert Opinion on Biological Therapy 2006;6:231–41.CrossRefGoogle ScholarPubMed
Allen, C, Saigal, K, Nottingham, L, et al. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-(kappa)B subunits in head and neck cancer. Molecular Cancer Therapeutics 2008;7:1949–60.Google Scholar
Li, C, Zang, Y, Sen, M, et al. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Molecular Cancer Therapeutics 2009;8:2211–20.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Squamous-cell carcinoma
    • By Carter Van Waes, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA, Yansong Bian, Laboratory of Cell and Developmental Biology, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA, Clint T. Allen, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA, John C. Morris, Metabolism Branch, National Cancer Institute, NIH, Bethesda, MD, USA, Zhong Chen, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA
  • Edited by Edward P. Gelmann, Columbia University, New York, Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, Frank J. Rauscher, III
  • Book: Molecular Oncology
  • Online publication: 05 February 2015
  • Chapter DOI: https://doi.org/10.1017/CBO9781139046947.062
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Squamous-cell carcinoma
    • By Carter Van Waes, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA, Yansong Bian, Laboratory of Cell and Developmental Biology, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA, Clint T. Allen, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA, John C. Morris, Metabolism Branch, National Cancer Institute, NIH, Bethesda, MD, USA, Zhong Chen, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA
  • Edited by Edward P. Gelmann, Columbia University, New York, Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, Frank J. Rauscher, III
  • Book: Molecular Oncology
  • Online publication: 05 February 2015
  • Chapter DOI: https://doi.org/10.1017/CBO9781139046947.062
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Squamous-cell carcinoma
    • By Carter Van Waes, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA, Yansong Bian, Laboratory of Cell and Developmental Biology, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA, Clint T. Allen, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA, John C. Morris, Metabolism Branch, National Cancer Institute, NIH, Bethesda, MD, USA, Zhong Chen, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda,MD, USA
  • Edited by Edward P. Gelmann, Columbia University, New York, Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, Frank J. Rauscher, III
  • Book: Molecular Oncology
  • Online publication: 05 February 2015
  • Chapter DOI: https://doi.org/10.1017/CBO9781139046947.062
Available formats
×